

IMEXTOR

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for **IMEXTOR**

(Imeglimin Hydrochloride Tablets 500 and 1000 mg) [Please refer the complete prescribing information for details].

PHARMACOLOGICAL PROPERTIES:

MECHANISM OF ACTION: Imeglimin is a drug that exerts a hypoglycemic effect through a glucose level dependent insulin secretion-promoting effect and an insulin resistance-improving effect, and its mechanism of action is presumed to be via an action on mitochondria.

INDICATIONS: It is indicated for type 2 diabetes mellitus.

DOSAGE AND ADMINISTRATION: As directed by the Physician. Tablets should be taken orally.

CONTRAINDICATION: Patients with a history of hypersensitivity to the ingredients of this drug, Patients with severe ketosis, diabetic coma or diabetic precoma, type 1 diabetes [immediate correction of hyperglycemia with transfusion and insulin is essential], Patients with severe infection, before or after surgery, or with serious trauma [Since blood sugar control by insulin injection is desired, administration of this drug is not suitable].

WARNINGS & PRECAUTIONS: Patients with renal dysfunction, it is recommended to perform renal function check regularly, as the excretion of this drug may be delayed and the blood concentration of this drug may increase, Since hypoglycemic symptoms may occur, care should be taken when administering to patients engaged in work at heights, driving a car, etc., If hypoglycemic symptoms are observed, take appropriate measures such as ingesting food containing carbohydrates. However, if hypoglycemic symptoms are observed due to concomitant use with a α -glucosidase inhibitor, glucose should be administered,

DRUG INTERACTIONS: Precautions for combined use. *Diabetes drug Insulin preparation Sulfonylurea Fast-acting insulin secretagogue α -glucosidase inhibitor Thiazolidine drug DPP-4 inhibitor GLP-1 receptor agonist SGLT2 inhibitor, etc:* The hypoglycemic effect may be enhanced. *Biguanide drugs:* The hypoglycemia effect may be enhanced. Gastrointestinal symptoms tend to occur more often, especially in the early stages of concomitant use. *Monoamine oxidase inhibitors:* The hypoglycemic effect may be enhanced. *Adrenocortical hormone thyroid hormone, etc:* The hypoglycemic effect may be enhanced.

ADVERSE REACTIONS: Cystitis, Loss of appetite, Diabetic retinopathy, diabetic retinal edema, macular edema, Vomiting, abdominal discomfort, dyspepsia, upper abdominal pain, loose stools, abdominal distension, gastroesophageal reflux disease, Nausea, diarrhea, constipation, Increased blood lactate, increased lipase, weight loss

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

IN/ IMEXTOR 500, 1000 mg/Dec 2022 /01/ABPI
(Additional information is available on request)